About A-Alpha Bio
A-Alpha Bio is a Healthcare company based in Seattle (United States) founded in 2017. It operates as a developer of cell-based tool for the measurements of protein interactions. A-Alpha Bio has raised $45.24 million across 10 funding rounds from investors including Gates Foundation, Xontogeny and U.S. Department of Defense. The company has 48 employees. A-Alpha Bio offers products and services including AlphaSeq and AlphaBind. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Proteomics. Its legal entity is A-ALPHA BIO, INC. Its competitors include Somalogic, Nautilus Biotechnology, Amunix, Biognosys and Elektrofi and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
A-Alpha Bio was founded in 2017 in Seattle, United States, within the biotechnology sector. A cell-based platform technology is provided by the company, utilizing engineered yeast cells to measure protein interactions. These tools support drug development processes by quantifying interaction dynamics. Operations focus on advancing research applications in protein biology, with services centered on precise measurement methodologies for pharmaceutical innovation.
- Headquarters Seattle, United States
- Employees 48
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website aalphabio.com
- Social LinkedIn X
- Legal Name A-Alpha Bio, Inc.
- Total Equity Funding$45.24M (USD)
in 10 rounds
- Latest Funding Round$14.5M (USD), Grant
May 2024
- InvestorsGates Foundation
& 12 more
- Employee Count48
Products & Services of A-Alpha Bio
A-Alpha Bio offers a comprehensive portfolio of products and services, including AlphaSeq and AlphaBind.
Platform for quantitative measurement of protein-protein interactions.
Tool for predicting protein binding from sequence data.
Funding Insights of A-Alpha Bio
A-Alpha Bio has successfully raised a total of $45.24M across 10 strategic funding rounds. The most recent funding activity was a Grant round of $14.5 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $45.24M
- Total Rounds 10
- Last Round Grant — $14.5M
- First Round $225,000
(Jul 2018)
- Investors Count 13
All 10 funding rounds of A-Alpha Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2024 | $14.5M | Grant | – | – | |
| Jul 2023 | $22.4M | Series A | – | Xontogeny | |
| May 2023 | $2.4M | Grant | – | – | |
| Sep 2021 | $20M | Series A | – | Madrona Venture Group | |
| Sep 2020 | $256,000 | Grant | – | – | |
| Jul 2020 | $800,000 | Grant | – | – | |
| May 2020 | $1.17M | Grant | – | – | |
| Sep 2019 | $2.84M | Seed | – | OS Fund | |
| Jul 2018 | $225,000 | Grant | – | – | |
| Jul 2018 | $225,000 | Grant | – | – |
13 investors in total: 13 institutional.
Investors in A-Alpha Bio
A-Alpha Bio has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, Xontogeny and U.S. Department of Defense.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage investments in science-driven companies are made. | – | breakout.vc | - | |
Life science startups are accelerated through focused programs by Xontogeny. | 2016 | xontogeny.com | Boston, United States | |
Venture capital investing in AI, biotech, and technology sectors, focusing on seed and early stages in Seattle and beyond. | – | madrona.com | - | |
Seed and early-stage technology companies are funded by Lux Capital. | – | luxcapital.com | Menlo Park, United States | |
Early-stage centric sector-agnostic VC firm investing in geographies such as the US | – | osfund.co | Chicago, United States | |
AME Cloud Ventures is focused on investing in data-driven technology companies. | – | amecloudventures.com | Palo Alto, United States | |
Investments in multiple sectors are made by Sahsen Ventures. | – | sahsen.com | Seattle, United States | |
Early-stage investments are made in Washington-based startups by WRF Capital. | – | wrfcapital.com | Seattle, United States | |
Venture capital fund backed by the US Government | – | seedfund.nsf.gov | Alexandria, United States | |
Military forces are provided by the U.S. Department of Defense for national security. | – | defense.gov | Washington, D.C., United States |
Investor details for A-Alpha Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of A-Alpha Bio
35 people are tracked at A-Alpha Bio (7 in leadership, 9 in board & advisors, 19 in team); the tracked headcount is 48.
| Name | Role | Group |
|---|---|---|
Randolph Lopez | Co-founder & CTO | Leadership |
Lisa Schubert | VP, Technical Operations & Engineering | Leadership |
Liz Fulton | Senior Director of Finance & Operations | Leadership |
David Younger | CEO | Leadership |
Ryan Emerson | VP Data Science | Leadership |
Adrian Lange | Director Of Machine Learning Research | Leadership |
Lisa S. | Vp, Technical Operations And Engineering | Leadership |
Heidi Hagen | Board Member | Board & advisors |
Matt McIlwain | Board Member | Board & advisors |
Eric Klavins | Scientific Advisor | Board & advisors |
Jade Brown | Scientific Advisor | Board & advisors |
Tony Polverino | Scientific Advisor | Board & advisors |
Lance Stewart | Scientific Advisor | Board & advisors |
Chris Gibson | Scientific Advisor | Board & advisors |
David Baker | Scientific Advisor | Board & advisors |
Lindy Fishburne | Board Observer | Board & advisors |
Paxton Reed | Research Associate II | Team |
Emily Engelhart | Principal Scientist | Team |
Cami Cordray | Technical Operations Manager | Team |
Aditya Agarwal | Senior Machine Learning Architect | Team |
15 more people are available in the full profile.
Complete people profiles for A-Alpha Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of A-Alpha Bio
3 dated milestones of A-Alpha Bio across 7 years, from founding to its latest funding, stage changes and deals.
- Founded A-Alpha Bio is founded.
- Funding First funding round of $225K.
- Funding Latest funding round, Grant, of $14.5M.
Competitors of A-Alpha Bio
A-Alpha Bio has 9 listed competitors in our database, 9 of them funded. They include Somalogic, Nautilus Biotechnology, Amunix, Biognosys and Elektrofi, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| somalogic.com | 1999 | Boulder, United States | $663.99M | 319 | Protein-based assays are developed for life science research. | |
| nautilus.bio | 2016 | Seattle, United States | $103.26M | 134 | A proteomics platform is developed for analyzing the human proteome. | |
| amunix.com | 2006 | Mountain View, United States | $200.59M | 82 | Peptide-based therapeutics are developed for cancers and immune disorders. | |
| biognosys.com | 2008 | Schlieren, Switzerland | $9.13M | – | Proteomics services are delivered via discovery and targeted platforms. | |
| elektrofi.com | 2016 | Boston, United States | $152.25M | 71 | Digital platform transforming the delivery of biologic medicines | |
| proteinsimple.com | 2004 | San Jose, United States | $114.29M | 157 | Provider tools to help researchers with protein analysis | |
| arzeda.com | 2008 | Seattle, United States | $94.96M | 66 | Synthetic enzymes are designed using computational technology for industrial applications. | |
| glyphic.bio | 2021 | San Francisco, United States | $39.2M | 26 | Next-generation protein sequencing platform is developed for proteome analysis. | |
| dynamic-biosensors.com | 2011 | Planegg, Germany | $5.83M | 51 | Label-free solutions for molecular interactions and biophysical analysis are provided. |
Detailed competitors of A-Alpha Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of A-Alpha Bio
The website of A-Alpha Bio (aalphabio.com) receives about 7K visits a month and ranks #4,649,731 among all websites worldwide, #5,540 in Biotechnology and Pharmaceuticals.
- Monthly visits7K
▲ 78.1% vs previous month
- Unique visitors1.9K
per month
- Global rank#4,649,731
among all websites
- Category rank#5,540
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit1.6
- Average visit7 sec
- DevicesDesktop 47% · Mobile 53%
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as A-Alpha Bio (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about A-Alpha Bio
Complete news archive for A-Alpha Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about A-Alpha Bio
A-Alpha Bio was founded in 2017 and raised its 1st funding round 1 year after it was founded.
A-Alpha Bio is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
A-Alpha Bio is a funded company, having raised a total of $45.24M across 10 funding rounds to date. The company's 1st funding round was a Grant of $225K, raised on Jul 2018.
A-Alpha Bio has 48 employees.
A-Alpha Bio was founded in 2017 in Seattle, United States, within the biotechnology sector. A cell-based platform technology is provided by the company, utilizing engineered yeast cells to measure protein interactions. These tools support drug development processes by quantifying interaction dynamics. Operations focus on advancing research applications in protein biology, with services centered on precise measurement methodologies for pharmaceutical innovation.
A-Alpha Bio's top competitors include Somalogic, Nautilus Biotechnology and Elektrofi.
A-Alpha Bio offers AlphaSeq and AlphaBind.
A-Alpha Bio has 13 investors. Key investors include Gates Foundation, Xontogeny, U.S. Department of Defense, Breakout Ventures, and Madrona.
A-Alpha Bio operates through A-Alpha Bio, Inc..